{
  "ticker": "LLY",
  "target_date": "2025-03-11",
  "actual_date": "2025-03-11",
  "collected_at": "2025-12-08T11:30:12.407233",
  "price": {
    "open": 822.49,
    "high": 827.61,
    "low": 807.02,
    "close": 819.3687133789062,
    "volume": 3796500,
    "change_1d_pct": -0.69,
    "change_7d_pct": -10.49,
    "change_30d_pct": 2.14
  },
  "technicals": {
    "rsi_14": 40.46,
    "sma_20": 877.54,
    "sma_50": 823.04,
    "macd": 10.207,
    "macd_signal": 21.547,
    "macd_histogram": -11.34,
    "bb_upper": 940.57,
    "bb_lower": 814.51,
    "price_vs_sma20_pct": -6.63,
    "price_vs_sma50_pct": -0.45,
    "volume_ratio": 1.07
  },
  "fundamentals": {
    "market_cap": 890638761984,
    "pe_ratio": 48.67761,
    "forward_pe": 43.84422,
    "price_to_book": 37.40625,
    "price_to_sales": 14.988922,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.65,
    "pct_from_52w_low": 59.27
  },
  "macro": {
    "spy": {
      "price": 551.09,
      "change_1d_pct": -0.83,
      "change_7d_pct": -4.77
    },
    "vix": {
      "level": 26.92,
      "signal": "HIGH_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.29
    },
    "dollar_index": {
      "level": 103.44
    },
    "gold": {
      "price": 2912.9
    },
    "regime": "BEAR_HIGH_VOL"
  },
  "news": [
    {
      "headline": "Viking Therapeutics: Finally, Here Comes The Buying Opportunity (Upgrade)",
      "source": "SeekingAlpha",
      "datetime": 1741696999,
      "summary": "Viking Therapeutics remains speculative despite progress in its clinical portfolio, notably the VK2735 program for obesity. Click here to read why VKTX is a Buy.",
      "url": "https://finnhub.io/api/news?id=ec3a005b2a5023dda2ad92ae7ddeb69830a5da30dcfb96186e3126d77332b8f6"
    },
    {
      "headline": "Invesco Charter Fund Q4 2024 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1741689000,
      "summary": "",
      "url": "https://finnhub.io/api/news?id=95c0176b47e7774f20184f6f2a105120cd484938174680e245d9781e4ecb23ba"
    },
    {
      "headline": "Merck opens vaccine manufacturing facility in North Carolina",
      "source": "Finnhub",
      "datetime": 1741678004,
      "summary": "Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, as the drugmaker seeks to boost its U.S. manufacturing in the face of President Donald Trump's tariff threats. ...",
      "url": "https://finnhub.io/api/news?id=ed71b4f0a7b63411271f5fc6937a3373ff5e5c2a814bc48eeef92d0d671fde65"
    },
    {
      "headline": "Amgen: Riding The MariTide Of Monthly Weight Loss",
      "source": "SeekingAlpha",
      "datetime": 1741625200,
      "summary": "Amgen stock rose 13% as obesity drug MariTide advances. Click here to find out why AMGN stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=3ec2b5102da8b330ae6a137f5e4d951e50cb5c459820cacda196d8a84ae9be96"
    },
    {
      "headline": "Novo Nordisk: CagriSema Disappoints Again",
      "source": "SeekingAlpha",
      "datetime": 1741611136,
      "summary": "Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, and stay competitive. Click for more.",
      "url": "https://finnhub.io/api/news?id=0a93f2015f1580d5dfe39a873aa02c717da2e058d2167fb48ae6257e0bbdc20c"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-04",
      "description": "xslF345X05/form4-03042025_040301.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000141588925006450/xslF345X05/form4-03042025_040301.xml"
    },
    {
      "form": "4",
      "date": "2025-03-03",
      "description": "xslF345X05/wk-form4_1741038785.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000083/xslF345X05/wk-form4_1741038785.xml"
    },
    {
      "form": "4",
      "date": "2025-03-03",
      "description": "xslF345X05/wk-form4_1741038712.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000081/xslF345X05/wk-form4_1741038712.xml"
    },
    {
      "form": "4",
      "date": "2025-02-26",
      "description": "xslF345X05/form4-02262025_040201.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000141588925005670/xslF345X05/form4-02262025_040201.xml"
    },
    {
      "form": "4",
      "date": "2025-02-25",
      "description": "xslF345X05/form4-02252025_040201.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000141588925005456/xslF345X05/form4-02252025_040201.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}